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Objectives: With the development of effective treatments and the resulting increase in life 
expectancy, bone mineral density (BMD) alteration has emerged as an important comorbidity 
in human immunodeficiency virus type-1 (HIV-1)-infected individuals. The potential contribu-
tors to the pathogenesis of osteopenia/osteoporosis include a higher prevalence of risk factors, 
combined antiretroviral therapy (cART)-exposure, HIV-1 itself and chronic immune activation/
inflammation. Dual-energy X-ray absorptiometry (DXA) is the “gold standard” technique for 
assessing bone status in HIV-1 population.
Methods: We conducted a cross-sectional study to investigate bone mineral status in a group of 
158 HIV-1-infected subjects. The primary endpoint was the feasibility of calcaneal quantitative 
ultrasound (QUS) as a screening tool for BMD. All subjects were receiving stable cART and 
were virologically suppressed (HIV-RNA <37 copies/mL) from at least 12 months. Calcaneal 
QUS parameters were analyzed to obtain information on bone mass and microarchitecture. The 
results were compared with those obtained by DXA.
Results: No correlations were found between DXA/QUS parameters and demographic or 
HIV-1-specific characteristics, also including cART strategies. In the univariate analyses 
BMD, QUS indexes, and Fracture Risk Assessment Tool scores conversely showed significant 
associations with one or more demographic or HIV-1-related variables. Moreover, a significant 
relationship between calcaneal quantitative ultrasound index/stiffness and femoral/lumbar BMD 
values from DXA was described. The multivariate analysis showed an independent association 
between calcaneal quantitative ultrasound index/stiffness and body mass index, higher CD4+ 
T-cell numbers and low 25-OH D2/D3 vitamin D levels <10 ng/mL (P-values: 0.004, 0.016, 
and 0.015, respectively).
Conclusion: As an alternative and/or integrative examination to DXA, calcaneal QUS could 
be proposed as a useful screening in HIV-1-infected patients for assessing bone health impair-
ment. In fact, the results obtained confirm that calcaneal QUS may be useful for monitoring 
bone status, being a noninvasive and inexpensive technique, especially in those subjects with the 
classical traditional risk factors for bone damage that were observed earlier in HIV-1 population.
Keywords: bone mineral density, fracture risk, calcaneal quantitative ultrasound, DXA 
Introduction
People living with human immunodeficiency virus type-1 (HIV-1) infection have a 
life expectancy quite similar to that of uninfected population due to the extensive 
use of combined antiretroviral therapies (cARTs) that have contributed to modifying 
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the disease prognosis.1 Aging with the virus (and on cART) 
is raising new challenges: “non AIDS-defining” cancers, 
cardiovascular diseases, bone diseases, and neurocognitive 
disorders are now considered a new set of comorbidities, 
and some of them are becoming significant causes of death 
among the HIV-1 population.2,3
Osteoporosis is a systemic skeletal disorder characterized 
by low bone mineral density (BMD) and microarchitectural 
deterioration of bone tissue, with a consequent raise in bone 
fragility and fractures. Its prevalence in HIV-1-infected sub-
jects is approximately threefold higher than in uninfected 
individuals.4 This increased prevalence is likely the result of 
heterogeneous causes and the interplay of host, viral, and 
cART-related factors. A reduced BMD with increased fracture 
risk has been yet demonstrated in both HIV-1-infected male 
and female population, compared with uninfected controls.5–7
HIV-1-infected patients also have a significantly higher 
prevalence of vertebral, hip, wrist, and combined fractures. 
The fracture rate was increased both in naïve and cART-
exposed subjects.8,9
Traditional osteoporosis risk factors such as low body 
mass index (BMI), cigarette smoking, alcohol abuse, gluco-
corticoid therapy, hypogonadism, growth hormone deficiency, 
and vitamin D insufficiency are more prevalent among HIV-
1-infected individuals and likely play a causative role, but 
also chronic immune activation and cART-related side effects 
should be considered.4,10,11
Low vitamin D levels are common in HIV-1-infected 
patients. The potential effect of cART on 25-OH D2/D3 
vitamin D levels has recently received a lot of  attention, 
due to emerging evidences that specific drugs may affect its 
levels with different mechanisms.12 Also coinfection with 
hepatitis C virus (HCV) in HIV-1-infected patients has been 
demonstrated as being an independent risk factor for both 
fragility-induced and other kinds of fractures.13 Moreover, 
initiation of cART is associated with bone loss regardless 
of the regimen selected, as for several comorbidities linked 
with HIV-1 infection. Indeed, the virus itself, determines per 
se an increase of bone loss and fracture risk.14,15
BMD can be measured by imaging modalities, such as 
dual-energy X-ray absorptiometry (DXA), which helps in 
identifying patients at high risk of fractures.16 Routine DXA 
screening of all HIV-1-infected patients on cART is not 
recommended. It is suggested to evaluate BMD by DXA 
scans in: 1) men aged 40–49 years or premenopausal women 
aged ≥40 years, who have an intermediate- or high-risk 
stratification by the Fracture Risk Assessment Tool (FRAX 
>10%, as 10-year risk of major osteoporotic fracture); 2) all 
postmenopausal women; 3) all men ≥50 years of age; and 4) 
adults with major fragility fracture risk factors regardless of 
age.17,18 Repeat DXA scanning should be considered after 1–2 
years for those with baseline advanced osteopenia and after 
5 years for mild-to-moderate osteopenia.19,20
Calcaneal quantitative ultrasound (QUS) is an attractive 
prescreening investigation for osteoporosis, being an alterna-
tive and/or integrative technique to DXA scan. It is a rela-
tively inexpensive, radiation-free, and transportable device, 
which has been recently proven to effectively predict fracture 
risk in elderly men and women. QUS uses high-frequency 
sound waves to evaluate bone properties. Multiple skeletal 
sites, such as tibia, phalanx, and radius, have been evaluated; 
however, the heel has been most widely studied because of 
several favorable characteristics, including the high content 
of trabecular bone and the high metabolic turnover. Although 
its use in clinical practice is still not well defined and depends 
on the type of device, it provides an appropriate tool for 
comparing BMD between different groups and identifying 
factors associated with variation in bone density, especially 
in settings where DXA is not available.21,22 Calcaneal QUS 
in a prescreen or stratification algorithm must be based on 
device-specific cutoff that have been validated in the popula-
tions for which they are intended to be used.23,24
In this context, we designed a cross-sectional study to 
measure the bone mineral quality in a group of HIV-1-in-
fected subjects on cART with the aim to assess the feasibility 
and usefulness of calcaneal QUS as a screening investigation 
for the bone evaluation in comparison to DXA.
Patients and methods
Study population
We performed a cross-sectional study to investigate the bone 
mineral status in a group of 158 HIV-1-infected subjects 
followed at the Department of Public Health and Infectious 
Diseases, University of Rome “Sapienza”. At baseline, infor-
mation regarding demographic characteristics, health-related 
behaviors, medical conditions, and prescribed medications 
were retrieved from the medical records. The following epide-
miological, immunovirological, and clinical factors increasing 
the osteoporosis risk were included: CD4+ T-cell nadir, current 
CD4+ T-cell count, HIV-RNA level, years of HIV-1 infection, 
AIDS diagnosis, time of cART exposure, boosted protease 
inhibitor (PI) exposure, tenofovir difumarate (TDF) expo-
sure, BMI, opiate, tobacco and alcohol use, hepatitis B virus 
(HBV) HCV coinfections, diabetes mellitus, renal function, 
prior or current corticosteroid use, hypogonadism, vitamin 
D deficiency, menopause, malabsorption, personal history 
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of fracture, parental history of hip fracture, and rheumatoid 
arthritis. Moreover, nontraumatic bone fractures were clini-
cally evaluated. Exclusion criteria were use of antiosteoporotic 
drugs, presence of chronic diseases known to be associated 
with osteoporosis, recent traumas or prolonged immobiliza-
tion. Fasting blood samples were obtained from all subjects 
and analyzed for vitamin D and parathyroid hormone (PTH) 
levels, as well as for serum alkaline phosphatase, total calcium 
and phosphates. Serum levels of 25-OH D2/D3 vitamin D 
were measured by electrochemiluminescence immunoas-
say (ECLIA) with the Elecsys vitamin D3 (25-OH) reactive 
(Roche Diagnostic GmbH, Mannheim, Germany) using the 
Roche/Hitachi COBAS E 601 clinical chemistry analyzer 
(Roche Diagnostics, Indianapolis, IN, USA). Renal function 
and glomerular filtration rate were estimated using  the Chronic 
Kidney Disease Epidemiology Collaboration equation.
BMI was calculated as the weight in kilograms divided 
by the square of the height in meters. The FRAX score and 
the Veterans Aging Cohort Study (VACS) index were also 
calculated to evaluate the 10-year probability of a major frac-
ture (spine, forearm, proximal humerus, or hip) or hip frac-
ture alone and to predict all-cause mortality, cause-specific 
mortality, and other outcomes in subjects living with HIV-1 
infection. The FRAX score is based on age, sex, weight, 
height, femoral neck BMD and the presence of clinical risk 
factors that increase the fracture occurrence. The VACS index 
(based on age, CD4+ T-cell count, HIV-1 RNA, hemoglobin, 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), platelets, creatinine, and HCV status) was validated 
for HIV-1-infected subjects in the Women’s Interagency 
HIV Study.25
Ethical permission from a review board was unnecessary 
for this study because the QUS analysis is routinely performed, 
as well as the DXA analysis, to evaluate BMD, in accordance 
with the current osteoporosis treatment guidelines. In Italy, 
the calcaneal QUS is an examination tool standardized and 
approved by the Ministry of Health with these indications.
Written informed consent was obtained from all subjects 
for the use of the QUS results (appropriately anonymized) 
for research purposes.
BMD analysis
BMD was assessed by DXA at the lumbar spine (L1–L4) and 
the femoral neck. T-scores were calculated using normative 
data based on reference data for European Caucasian females 
matched for age, sex, and race. According to current interna-
tional guidelines, osteopenia and osteoporosis were defined 
by a T-score of <−1 and <−2.5, respectively.26 The evaluation 
of the bone status was also investigated using the calcaneal 
QUS (Hologic Sahara, Hologic, Inc., Marlborough, MA, 
USA). QUS measures the time taken for sound waves to travel 
between the two transducers, referred to as speed of sound. 
The rate of ultrasound attenuation is defined as broadband 
ultrasound attenuation. Both speed of sound and broadband 
ultrasound attenuation are reduced in the presence of reduc-
tions in bone density and trabecular number. Hologic Sahara® 
also provides a combination “stiffness” index, referred to as 
quantitative ultrasound index (QUI).
Statistical analysis
Data were summarized as proportions and medians with 
interquartile ranges (IQR). Binary correlations between 
quantitative variables were analyzed using the Spearman’s 
rank correlation test. Predictive variables for the presence of 
low calcaneal QUI/stiffness values were identified in a mul-
tivariable logistic regression model that used as dependent 
variable the presence of values of calcaneal QUI/stiffness 
in the first decile (below the tenth centile) of the distribu-
tion, with adjusted odds ratios and 95% confidence intervals 
calculated. The variables entering the model (independent 
variables) were selected based on the best fitting in terms of 
model discrimination (accuracy of the model to predict cases 
in the first decile and area under the curve in receiver opera-
tor characteristic [ROC] curves), and amount of the variation 
explained by the model (Nagelkerke R square). For all tests, 
P-values <0.05 were considered significant. All statistical 
analyses were performed with the SPSS software, version 22 
(IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
A total of 158 consecutive HIV-1-infected patients, followed 
at the Department of Infectious Diseases, “Sapienza” Uni-
versity of Rome, were included in the study between May 
and November 2014. All the subjects were receiving a stable 
and effective cART and  a PI (n=52) or a nonnucleoside 
reverse-transcriptase inhibitor (NNRTI, n=71) or an integrase 
inhibitor (INI, n=35) in the scheme and were all virologically 
suppressed (HIV-RNA levels below <37 copies/mL) from at 
least 1 year. The population was characterized by a long his-
tory of HIV-1 infection (median: 17 years) and antiretroviral 
treatment (median: 15 years), good immunological status 
(median CD4: 622 cells/mm3), and relatively low values of 
the VACS index, suggesting overall good clinical conditions 
and limited risk of mortality. The general characteristics of 
the population are reported in detail in Table 1.
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Table 1 Population characteristics
Parameter Median (IQR) N (%)
Age, years 52 (46–56)
BMI, kg/m2 22.8 (20.9–25.4)
Time since HIV diagnosis, years 18 (11–23)
Prior cART exposure, years 15 (10–20)
Prior PI exposure, years 5 (0–9)
Prior TDF exposure, years 5 (3–7)
CD4+ T-cell nadir, cells/µL 168 (108–295)
Current CD4+ T-cells, cells/µL 622 (460–860)
Hgb, g/dL 14.3 (13.6–15.3)
Platelets ×1,000/µL 208 (172–245)
ALT, U/L 23 (16–33)
AST, U/L 22 (18–31)
HDL cholesterol, mg/dL 50 (40–62)
LDL cholesterol, mg/dL 115 (95–147)
Serum creatinine, mg/dL 0.8 (0.7–1.0)
e-GFR (CKD-EPI), mL/min/1.73 m2 89.3 (76.9–103.5)
VACS index 16 (6–23)
Sex, male 107 (67.7)
HBV coinfection 6 (3.9)
HCV coinfection 39 (25.2)
Current cART:
PI-based
NNRTI-based
INI-based
52 (32.9)
71 (44.9)
35 (22.2)
NRTI in the regimen:
None
3TC only
TDF only
ABC+3TC
TDF+FTC
34 (21.9)
3 (1.9)
3 (1.9)
44 (28.4)
71 45.8)
HIV disease stage:
CDC-A
CDC-B
CDC-C
55 (36.2)
55 (36.2)
42 (27.6)
Lumbar mineralization status:
Normal
Osteopenia
Osteoporosis
66 (53.7)
44 (35.8)
13 (10.6)
Femoral mineralization status:
Normal
Osteopenia
Osteoporosis
56 (45.2)
57 (46.0)
11 (8.9)
Abbreviations: ABC, abacavir; BMI, body mass index; cART, combined 
antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CKD-EPI, 
Chronic Kidney Disease Epidemiology Collaboration; e-GFR, estimated glomerular 
filtration rate; FTC, emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; 
HDL, high-density lipoproteins; Hgb, hemoglobin; HIV, human immunodeficiency 
virus; INI, integrase inhibitor; IQR, interquartile range; LDL, low-density lipoprotein; 
NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleos(t)ide reverse 
transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir difumarate; VACS, 
Veterans Aging Cohort Study; 3TC, lamivudine.
Table 2 Bone metabolism and mineralization indexes of enrolled 
patients
Parameter Median (IQR) N (%)
25-OH D2/D3 vitamin D, ng/mL 27.8 (15.3–38)
PTH, pg/mL 46.9 (31.9–58.2)
Serum phosphate, mg/dL 3.1 (2.8–3.4)
Calcaneal QUI/stiffness, % 78.1 (66.2–90.6)
Calcaneal T-score –1.5 (–0.7–2.3)
Calcaneal BMD, g/cm2 0.42 (0.34–0.50)
Lumbar spine BMD, g/cm2 0.97 (0.87–1.12)
Femoral BMD, g/cm2 0.84 (0.73–0.98)
FRAX score, % 2.9 (2.1–4.8)
25-OH D2/D3 vitamin D levels <30 ng/mL 73 (54.9)
25-OH D2/D3 vitamin D levels <10 ng/mL 14 (10.5)
PTH levels >65 pg/mL 18 (18.4)
Femoral osteoporosis or osteopenia  68 (54.9)
Femoral osteoporosis 11 (8.9)
Lumbar osteoporosis or osteopenia 57 (46.4)
Lumbar osteoporosis 13 (10.6)
Summary of clinical risk factors for 
osteoporosis:
 Menopausal status
 Type 2 diabetes mellitus
 Current or ex tobacco smoker
 HBV or HCV coinfection
 Hypogonadism
25 (16.1)
20 (12.9)
101 (65.2)
45 (29.0)
2 (1.3)
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment 
Tool; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; PTH, 
parathyroid hormone; QUI, quantitative ultrasound index.
Patients were analyzed for clinical and treatment variables 
according to the different cART used at the enrollment: no 
statistically significant differences were observed when 
age, sex, risk of HIV-1 transmission, BMI, cigarette smok-
ing, HBV and HCV coinfections, nadir and current CD4+ 
T-cell counts were considered. However, subjects taking an 
INI-based therapy had a significantly longer extent of HIV-1 
infection (20.5±6 vs 15.3±8.3 years, P<0.005) compared 
with those using a PI- or a NNRTI-based cART. Again, a 
similar result was observed when the years of prior anti-
retroviral therapy were considered (17.5±5.1 vs 12.9±7.2 
years, P<0.004), or the VACS index was included (21.3±11.8 
vs 13.1±10.9, P<0.002). Moreover, similar findings were 
observed in subjects belonging to the PI group when com-
pared to those taking an NNRTI-based regimen at baseline. 
Years of prior TDF exposure were comparable in all groups 
(data not shown).
Evaluation of bone indexes
The evaluation of bone status, based on several indexes, 
is reported in Table 2. Blood tests revealed a frequent 
occurrence (45.1%) of low vitamin D levels (<30 ng/mL). 
Increased levels of PTH (>65 pg/mL) were found in almost 
20% of cases. All subjects had serum calcium levels within 
the normal range, while 14/152 (9.2%) had hypophospha-
temia (<2.5 mg/dL). Most of them (11/14) had one or more 
of the following potentially predisposing conditions: TDF-
based regimens (9), increased PTH levels (1), diabetes (3), 
estimated glomerular filtration rate (e-GFR) <60 mL/min 
(1), or decreased serum vitamin D levels (5).
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Figure 1 Correlations between QUI/stiffness  index and lumbar BMD (A), femoral BMD (B), FRAX score (C), and BMI (D).
Abbreviations: BMD, bone mineral density; BMI, body mass index; FRAX, Fracture Risk Assessment Tool; QUI, quantitative ultrasound index.
The instrumental assessment of the bone compartment 
showed a common occurrence of reduced BMD: median 
BMD levels at the lumbar, femoral, and calcaneal sites were, 
respectively (with IQR): 0.97 (0.87–1.12), 0.84 (0.73–0.98), 
and 0.42 g/cm2 (0.34–0.50). Osteoporosis or osteopenia 
were found at the level of lumbar spine in 46.4% of subjects 
and at the level of femoral neck in 54.9% of subjects. Cal-
caneal QUI/stiffness showed a median value of 78.1 (IQR 
66.2–90.6), with a median calcaneal T-score of −1.5.
The presence of clinical risk factors for osteoporosis was 
very common: 101 patients (65.2%) were active (or prior) 
tobacco smokers, 45 (29.0%) were coinfected with HBV and/
or HCV, 20 had type 2 diabetes mellitus (12.6%), almost half 
of the women (25/51, 49%) were menopausal, and two males 
were affected by hypogonadism. The values of FRAX score 
were usually low, with only 8/152 (5.2%) showing a 10-year 
estimated risk of fractures higher than 10%. Posttraumatic 
fractures were reported by three subjects, whereas no occur-
rence of osteoporotic fractures was reported.
We then explored possible predictors of abnormalities 
in the main bone indexes evaluated. In univariate analyses, 
BMD levels, FRAX score, and QUIs were substantially unaf-
fected by e-GFR, smoking, Centers for Disease Control and 
Prevention (CDC) HIV-1 disease stage, presence of diabetes, 
and current use of INIs. BMD, QUS indexes, and FRAX 
scores conversely showed significant associations with one 
or more of the following variables: sex, menopause, HCV or 
HBV coinfection, CD4+ T-cell levels, and vitamin D status 
(data not shown).
The calcaneal QUI/stiffness was highly and positively 
correlated with BMI values (P=0.010), with the BMD mea-
sures taken at the lumbar and femoral sites (P-values: 0.008 
and <0.001, respectively) and showed an inverse significant 
correlation with the risk of fracture as expressed by the FRAX 
score (P=0.006) (Figure 1).
Assuming its potential role as a screening test, the 
determinants of low values of calcaneal QUI/stiffness were 
evaluated in a multivariate analysis. The variables in the equa-
tion of the final model, with adjusted odds ratios (with 95% 
confidence interval) for each variable are shown in Table 3.
The three variables significantly and independently asso-
ciated with low QUI/stiffness values were BMI (with higher 
BMI protective in terms of risk of low QUI/stiffness), CD4+ 
T-cell count (with higher CD4+ numbers associated with 
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Table 3 Multivariate analysis of determinants of low calcaneal QUI/stiffness (<10° percentile)
Parameters AOR AOR 95% CI P-value
Lower Upper
HCV coinfection 0.349 0.018 6.760 0.487
BMI (per unitary increase) 0.699 0.548 0.891 0.004 
Duration of previous TDF exposure (per additional year) 0.945 0.644 1.388 0.773
Duration of previous PI exposure (per additional year) 1.226 0.965 1.557 0.095
Menopause 8.787 0.464 166.350 0.148
CDC-C stage 9.329 0.781 111.355 0.078
CD4+ T-cells/µL (per unitary increase) 1.004 1.001 1.007 0.016
Years from HIV-1 diagnosis (per unitary increase) 0.963 0.826 1.124 0.635
Serum 25-OH D2/D3 vitamin D levels <10 ng/mL 35.585 2.003 632.266 0.015
Diabetes 2.233 0.135 36.821 0.574
Currently on TDF-based regimens 1.457 0.155 13.702 0.742
Serum PTH levels (>65 pg/mL) 1.144 0.059 22.115 0.929
Notes: Bold values indicate statistical significance (P<0.05). Fitting of the model: Nagelkerke R square: 0.853; predictive accuracy: 93.8%; area under the curve (ROC): 0.903.
Abbreviations: AOR, adjusted odds ratio; BMI, body mass index; CDC, Centers for Disease Control and Prevention; CI, confidence interval; HCV, hepatitis C virus; HIV-1, 
human immunodeficiency virus type-1; PI, protease inhibitor; PTH, parathyroid hormone; QUI, quantitative ultrasound index; TDF, tenofovir difumarate.
higher risk of low QUI/stiffness) and low (<10 ng/mL) serum 
levels of 25-OH D2/D3 vitamin D, which increased >30-fold 
the risk of low QUI/stiffness values (Table 3).
Discussion
HIV-1-infected adults are at high risk of low BMD, with up 
to 60% prevalence of osteopenia and up to 15% prevalence of 
osteoporosis. The initiation of treatment in ART-naive adults 
is associated with 2%–6% loss of BMD after 48–96 weeks 
of therapy, then followed by stabilization.27,28 The observed 
changes are similar, whether the regimen includes an INI or 
NNRTI; however, the decrease in BMD appears to be greater 
with TDF than with other NRTIs or when a PI is included.18 
Recent findings suggest that HIV-1 infection and/or height-
ened inflammation could impact BMD loss in HIV-1-infected 
subjects, independently from cART effects.15 Several ques-
tions are still unresolved about the role of antiretroviral 
therapy in bone demineralization. In fact, the mechanism 
leading to the acute decrease in BMD after cART initiation 
is unclear; in addition, although a partial BMD recovery is 
observed after the first year of therapy or after the switch to 
another cART regimen, long-term clinical impact of initial 
BMD loss has not been clarified yet.
Some cross-sectional studies have reported a higher preva-
lence of low BMD, osteoporosis and fractures in HIV-1-posi-
tive adults when compared with HIV-1-negative controls.29,30 
Monitoring changes in bone structure and mineral density 
is pivotal in the management of HIV-1 population because 
the viral infection and certain combinations of antiretroviral 
treatments elicit progressive bone loss in these patients.31
Currently, DXA is the “gold standard” technique for the 
assessment of the bone status in HIV-1 population, both at 
the time of diagnosis as well as during the first months of 
antiretroviral treatment. However, DXA suffers from several 
technical limitations, as it quantifies bone mass but does not 
provide information on bone quality. The DXA technique 
is not able to determine the strength of bone architecture, 
and a normal BMD could be associated with impaired bone 
structure and a higher risk of fractures.32 These limitations 
explain why HIV-1-infected patients may often present a 
fracture risk largely exceeding that expected from DXA 
evaluation.
Calcaneal QUS provides information on both bone mass 
and bone microarchitecture. Notwithstanding as an alterna-
tive and/or integrative technique to DXA, quantitative cal-
caneal ultrasound has recently been proposed as a screening 
method for osteopenia/osteoporosis, since it has been proven 
to be accurate and precise in evaluating bone mass. It is a 
noninvasive and low-cost technique that can be evenly used 
for assessing structure and bone mineralization. In seronega-
tive patients, some studies had revealed that QUS is a cheap 
tool that gives an accurate and precise evaluation of bone 
mass and acts as an early predictive marker of bone damage. 
In a recent meta-analysis, one limitation emerged of QUS 
devices is the absence of standardized cutoffs between dif-
ferent manufacturers, thus limiting the comparison between 
results obtained from the different devices. However, the 
authors concluded that, in several of the available studies, 
the use of QUS could help save patients from undergoing 
DXA scans.22–24
In all HIV-1-infected men aged 40–49 years and in 
premenopausal women aged ≥40 years, the risk of fragility 
fracture should be assessed primarily using the FRAX score, 
without performing DXA, as it includes the use of clinical 
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risk factors to estimate the 10-year fracture risk in individu-
als older than 40 years. BMD obtained by DXA should be 
incorporated in the algorithm, when available. Moreover, it 
is recommended to consider HIV-1 infection as a secondary 
cause of osteoporosis, including it in the FRAX calculator 
tool. DXA scan should be reserved for postmenopausal 
women, men ≥50 years old, and those showing the following: 
history of low impact fracture, high risk for falls, clinical 
hypogonadism, and oral glucocorticoid use (minimum 5 mg/
daily prednisone equivalent for >3 months). Preferably, DXA 
should be performed in those with above the risk factors 
prior to cART initiation.17,18 Moreover, according to previ-
ous observations, also subjects with a poor immunological 
recovery after starting cART should be considered, as they 
are more vulnerable to develop bone fractures.6,33
In our study, we perform a bone status evaluation in HIV-1-
infected individuals by means of the calcaneal QUS technique, 
using it as a screening tool in the assessment of bone health in 
this population, and comparing the results acquired with those 
obtained by DXA. Considering the progressive “aging” and 
the “frailty” condition described in HIV-1-infected patients, it 
would be important to have a screening instrument easy enough 
to perform in different clinical settings for the evaluation of 
bone mineral impairment. So, it would be appropriate carry-
ing out calcaneal QUS as a screening examination of bone 
quality in daily clinical practice, mainly in those subjects with 
low BMI, smokers and persons who use alcohol, as well as 
in patients with diabetes mellitus, in perimenopausal women, 
and in male population, as these are osteoporosis risk factors 
or conditions frequently observed in the HIV-1 population.
Our results confirm that clinical risk factors for osteo-
porosis are very common in HIV-1-infected subjects and 
that there is a high prevalence of bone alterations in our 
population, as the occurrence of osteopenia/osteoporo-
sis at the femoral neck was >50%. These findings were 
confirmed by the increased impairment of calcaneal QUI/
stiffness, with the lower values observed when osteopenia 
or osteoporosis were detected by DXA. The univariate 
analysis confirms as predictors of BMD, QUS indexes, and 
FRAX scores abnormalities several variables, such as sex, 
menopause, HCV or HBV coinfection, CD4+ T-cell levels, 
and vitamin D status. The correlation observed between 
QUI/stiffness and HCV infection, despite unconfirmed 
in the multivariate analysis, support the need of making 
a specifically targeted screening with calcaneal QUS in 
the setting of HIV/HCV coinfected patients. In fact, HCV 
coinfection is associated with a greater risk of osteoporosis 
and fractures than HIV-1 monoinfection; these data advise 
that HIV/HCV coinfected individuals should be targeted 
for fracture prevention through risk factor modifications 
at all ages and DXA screening after 40 years.
The calcaneal QUI/stiffness was highly and positively 
correlated with the DXA BMD measures taken at the lum-
bar and femoral sites: this relationship suggests that the 
bone stiffness measured by calcaneal QUS may have an 
early predictive value in the assessment of bone status in 
HIV-1-infected subjects. As expected, there was a positive 
correlation between QUI/stiffness and BMI, as it indirectly 
represent an indicator of the general status of the subjects. 
Conversely, this QUS index was inversely correlated with 
the FRAX score, thus indicating its utility in predicting an 
increased risk of bone fractures in those subjects showing 
low values of QUI/stiffness.
Given its potential role as a screening test, we evaluated 
the determinants of low values of calcaneal QUI/stiffness in 
a multivariate analysis. Three variables were significantly 
and independently associated with low QUI/stiffness values: 
a higher BMI value was protective, as it indirectly represents 
a subject in good clinical conditions, whereas higher CD4+ 
T-cell counts were associated with a greater risk of low QUI/
stiffness, probably reflecting a paradoxically negative effect 
of prolonged drug exposure and viral suppression in our 
population. On the contrary, the low (<10 ng/mL) serum 
levels of 25-OH D2/D3 vitamin D increased >30-fold the 
risk of low QUI/stiffness values, thus confirming the cen-
tral role exerted by vitamin D in preserving a normal bone 
metabolism.
Accordingly, with these findings, the implementation of 
calcaneal QUS in the daily clinical practice may be consid-
ered an alternative to DXA in different settings for diagnosing 
osteopenia/osteoporosis in HIV-1-infected patients.
In some studies, a direct activity of different antiret-
roviral drugs on bone mineral quality and turnover has 
been described.14,34 Moreover, a recent study suggests a 
better impact of INIs vs PIs on bone mineral status.35 Our 
study apparently does not confirm such a result, as a direct 
relationship between calcaneal QUI/stiffness, BMD, and 
the cumulative TDF or PI exposure has not been found. 
The same finding has been observed when PI use was 
compared to NNRTI- or INI-based regimens. Moreover, 
no differences were found when the backbone use was 
compared. These different results observed could be due 
to the study design (cross-sectional) and/or to the relative 
low sample size of subjects investigated. Probably these 
limitations may be overwhelmed by the inclusion of addi-
tional analyses, such as the investigation of bone turnover 
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markers and/or the evaluation of immune activation and 
inflammation markers, whose usefulness has been already 
described in HIV-related BMD alterations.
Anyway, the results obtained in our study clearly support 
the inclusion of calcaneal QUS as a complementary tool to 
DXA, which is useful for predicting the risk of bone fractures 
in HIV-1-infected patients, both when they start cART as well 
as during its follow-up.
Conclusion
Calcaneal QUS may be useful to monitor the impact of 
viral infection and antiretroviral drugs on bone status, being 
a noninvasive and inexpensive technique, easy to perform 
in the daily clinical practice, and requiring a short time for 
implementation. Using a careful monitoring of calcaneal 
QUS stiffness, FRAX score, and some markers of bone 
turnover, could be a key to reserve DXA examination only 
for selected patients.
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